Combination of OV therapies with CAR-T cells have shown efficacy in pre-clinical models; for example, an oncolytic adenovirus armed with a PDL1 blocking mini-antibody enhanced the anti-tumour efficacy of HER2 specific CAR-T cells in murine models of solid tumours[114]. Here, CD274 is linked to neoplasm.